Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Chatterjee, Arjun ^a   Shah, Manan ^b   D'Souza, Anna O ^b   Bechtel, Benno ^c   Crater, Glenn ^c   Dalal, Anand A ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b XCENDA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Add on therapy; Chronic obstructive pulmonary disease; Cost; Emergency room visit; Exacerbation; Hospitalization; Pharmacoeconomics; Pharmacotherapy; Triple therapy

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ADD ON THERAPY; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DISEASE COURSE; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; RISK; TREATMENT OUTCOME;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84856988484     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-15     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009 Medical Communications Resources, Inc 2009, Available at: http://www.GOLDCOPD.com. Accessed 15 February 2010, Global Initiative for Chronic Obstructive Lung Disease.
2. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122:47-55. 10.1378/chest.122.1.47, 12114338.
3. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
4. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965. 10.1378/chest.115.4.957, 10208192.
5. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091. 10.1164/rccm.2112055, 12379552.
6. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. 10.1183/09031936.03.00031402, 12570112.
7. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843. 10.1378/chest.124.3.834, 12970006.
8. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, (4):CD003794.
9. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, (4):CD006829.
10. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, (4):CD006826.
11. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003, 2:67-74.
12. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
13. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006, 11:598-602. 10.1111/j.1440-1843.2006.00889.x, 16916333.
14. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008, 63:592-598. 10.1136/thx.2007.087213, 18245142.
15. Welte R, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750. 10.1164/rccm.200904-0492OC, 19644045.
16. Welte T. Optimising treatment for COPD---new strategies for combination therapy. Int J Clin Pract 2009, 63:1136-1149. 10.1111/j.1742-1241.2009.02139.x, 2739483, 19624783.
17. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine 2011, doi:10.1016/j.rmed.2011.09.002.
18. Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008, 14:438-448.
19. ISPOR international digest of databases IMS LifeLink Health Plan Claims Database. 2009, Available at: http://www.ispor.org/DigestOfIntDB/Default.aspx?rcd=426. Accessed 12 February 2010, ISPOR international digest of databases.
20. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
22. Schmier JK, Halpern MT, Higashi MK, Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res 2005, 14:329-347. 10.1007/s11136-004-0625-1, 15892423.
23. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. Scientific review. JAMA 2003, 290:2301-2312. 10.1001/jama.290.17.2301, 14600189.
24. Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation-a systematic review. Int J Chron Obstruct Pulmon Dis 2007, 2:241-251. 2695199, 18229562.
25. Almagro P, Barreiro B, Ochoa de Echaguen A, Quintana S, Rodríguez Carballeira M, Heredia JL, Garau J. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration 2006, 73:311-317. 10.1159/000088092, 16155352.
26. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, Mariotta S, Ricci A, Vitarelli A, Puglisi G, De Vito C, Villari P, Allegra L. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010, 188:321-329. 10.1007/s00408-009-9222-y, 20066539.
27. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002, 19:182-191. 10.1183/09031936.02.00283202, 11843317.
28. Hanania NA, Niewoehner DE, Crater GD, Emmett A, O'Dell D, Cicale MJ. Triple therapy of fluticasone propionate/salmeterol combination 250/50 mcg and tiotropium improves lung function compared to tiotropium monotherapy. Abstract. Chest 2010, 138:867A.
29. Jones PW. Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice?. Am J Respir Crit Care Med 2009, 180:689-690. 10.1164/rccm.200908-1205ED, 19805796.
30. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009, 6:320-329. 10.1080/15412550903140881, 19863361.
31. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102:1099-1108. 10.1016/j.rmed.2008.04.019, 18614347.
32. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009, 169:1403-1410. 10.1001/archinternmed.2009.233, 19667304.
33. Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008, 30 Spec No:1003-1016.